Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Short Interest Update

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) saw a large increase in short interest in the month of November. As of November 15th, there was short interest totalling 3,890,000 shares, an increase of 6.0% from the October 31st total of 3,670,000 shares. Based on an average daily volume of 493,300 shares, the days-to-cover ratio is presently 7.9 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Aldeyra Therapeutics in a report on Friday, August 9th.

Hedge Funds Weigh In On Aldeyra Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Barclays PLC boosted its position in Aldeyra Therapeutics by 280.1% in the third quarter. Barclays PLC now owns 65,561 shares of the biotechnology company’s stock valued at $353,000 after buying an additional 48,313 shares in the last quarter. State Street Corp lifted its position in shares of Aldeyra Therapeutics by 1.7% during the third quarter. State Street Corp now owns 973,908 shares of the biotechnology company’s stock worth $5,249,000 after purchasing an additional 16,188 shares in the last quarter. Jacobs Levy Equity Management Inc. lifted its position in shares of Aldeyra Therapeutics by 163.4% during the third quarter. Jacobs Levy Equity Management Inc. now owns 476,949 shares of the biotechnology company’s stock worth $2,571,000 after purchasing an additional 295,864 shares in the last quarter. Paloma Partners Management Co acquired a new position in shares of Aldeyra Therapeutics during the third quarter worth approximately $62,000. Finally, PDT Partners LLC acquired a new position in shares of Aldeyra Therapeutics during the third quarter worth approximately $169,000. 59.71% of the stock is currently owned by institutional investors and hedge funds.

Aldeyra Therapeutics Trading Down 1.6 %

NASDAQ ALDX opened at $4.82 on Tuesday. The company’s 50-day simple moving average is $5.21 and its 200 day simple moving average is $4.67. Aldeyra Therapeutics has a twelve month low of $2.71 and a twelve month high of $6.55. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.80 and a quick ratio of 6.80.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its earnings results on Thursday, November 7th. The biotechnology company reported ($0.25) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.25). As a group, analysts predict that Aldeyra Therapeutics will post -0.92 earnings per share for the current fiscal year.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.